General Psychiatry - Articles - Page 92

Assessing and Working with Patients with Cognitive Impairment and Dementia

March 1, 2015

Marc Agronin, MD Geriatric Psychiatrist Vice President, Behavioral Health and Clinical Research Miami Jewish Health Systems, Miami, FL Dr. Agronin has disclosed that he is principal investigator on research grants from several pharmaceutical firms and that all funds go directly to his employer, Miami Jewish Health Systems. In addition, he has been on the speakers bureaus of Forest Laboratories (Namenda XR), AssurX (GeneSightRX), and Novartis (Exelon Patch). Dr. Carlat has reviewed the content of the interview and has determined that there is no bias due to these relationships.

Get advice on how to assess and work with patients with cognitive impairment and dementia, in an interview with Marc Agronin, MD, Geriatric Psychiatrist and Vice President of Behavioral Health and Clinical Research at Miami Jewish Health Systems.

Anticholinergics and Dementia

March 1, 2015

Many medications have anticholinergic side effects, which can be particularly troublesome for the elderly.

Intensive Weight Loss Program for Psychiatric Patients Yields Mediocre Results

March 1, 2015

A recent study tested an intensive weight loss program in a large group of psychiatric patients. The results were…well, read on and you decide whether they were impressive.

Learning Objectives, Topics in Geriatric Psychiatry, TCPR, March 2015

March 1, 2015

After reading these articles, you should be able to…

Latuda: An Evaluation of Its Usefulness

February 1, 2015

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

The New Emphasis on Community Functioning in Schizophrenia

February 1, 2015

Dost Ongur, PhD, MD and Daniel Carlat, MD

Dost Ongur, PhD, MD Chief, Psychotic Disorders Division, McLean Hospital, Belmont, MA Associate Professor of Psychiatry, Harvard Medical School Dr. Ongur has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity. Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.

Suicide: Family History and Suicide Attempts

February 1, 2015

We’ve known for some time that if your patient has a parental history of a mood disorder or suicide attempt, his or her risk of a suicide attempt increases, and a new study adds some more information that might help us prevent bad outcomes.

FDA Issues Alert for Geodon

February 1, 2015

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.